Targeted drug treatment for pancreatic cancer using pathway changes
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and willing to sign informed consent
- Have confirmed pancreatic ductal adenocarcinoma, and at least one tumor spot that can be biopsied
- Be well enough for treatment (ECOG 0 to 2) and able to visit for follow-ups
- Have blood counts and organ labs in required ranges (often hemoglobin, white cells, neutrophils, platelets, kidney and liver tests)
- Be able to take pills by mouth and have no bowel or stomach problems that stop absorption
- Be able to undergo required repeat tumor biopsies during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
Hear when a new Locally Advanced Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.